Kuala Lumpur, Malaysia – From July 27 to July 29, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the 14th Interventional Cardiovascular Society of Malaysia ("ICSM") Annual Conference - MYLIVE. With around 1,000 professionals and physicians in attendance, the congress aims to improve their understanding in cardiovascular diseases by academic exchange, and share the latest advancement of cardiovascular interventional treatment.
On July 28, a complex live case of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") was broadcasted during the congress. The case was performed by Dr. Mathew Samuel Kalarickal from India to treat a 70-year-old patient suffering from double vessels disease with calcified LCX and CTO at distal LAD. Dr. Mathew decided to adopt rotational atherectomy to treat the calcified lesion at first, and then implanted four Firehawk® stents (3.0*18mm, 2.25*29mm, 2.5*33mm, 3.0*13mm) in the LCX and LAD lesions. The operation achieved successful outcome, which was well recognized by experts in attendance. Dr. Mathew spoke highly of the excellent crossability of Firehawk® and shared the three-month Optical Computerized Tomography ("OCT") data from the TARGET All Comer trial, the first post-market large-scale, randomized trial in Europe for Firehawk®.
The revolutionary third-generation drug-eluting stent Firehawk® is the result of eight years of research and development of MicroPort® and it is the world's first and only target eluting stent. The live case broadcasted in the 2017 Malaysia Live once again proved the outstanding performance of Firehawk®. Previously, MicroPort® and the Ministry of Health of Malaysia jointly launched TARGET MALAYSIA REGISTRY, a large-scale, perspective, multi-center, single-arm observational registry trial for Firehawk®, by which MicroPort® hopes to further assess and seek for more evidence for the safety and efficacy of Firehawk® in a real world population to provide ideal solutions for local patients with cardiovascular disease.